Update on Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer
Author Information
Author(s): Mokbel Ramia, Karat Isabella, Mokbel Kefah
Primary Institution: St. George's Hospital, London, UK
Hypothesis
Optimal adjuvant endocrine therapy for hormone sensitive breast cancer in postmenopausal women should include a third generation aromatase inhibitor.
Conclusion
Adjuvant anastrozole or letrozole should be used upfront in postmenopausal women with high risk disease.
Supporting Evidence
- Anastrozole significantly prolonged disease-free survival and reduced the risk of recurrence by 26%.
- Letrozole significantly reduced the risk of recurrence by 28% in hormone-receptor positive disease.
- Sequential therapy with tamoxifen followed by an AI showed significant improvement in disease-free survival.
Takeaway
Women with certain types of breast cancer should take specific medications to help prevent the cancer from coming back after treatment.
Methodology
The article reviews various studies comparing the effectiveness of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer.
Limitations
Further research is required to establish the long-term cardiovascular safety of AIs and the optimal duration of therapy.
Participant Demographics
Postmenopausal women with hormone receptor positive breast cancer.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI 0.64–0.87
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website